Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute.
Wilkes JD, Fidias P, Vaickus L, Perez RP. Wilkes JD, et al. Among authors: vaickus l. Cancer. 1995 Oct 15;76(8):1377-87. doi: 10.1002/1097-0142(19951015)76:8<1377::aid-cncr2820760813>3.0.co;2-m. Cancer. 1995. PMID: 8620412 Review.
Overview of monoclonal antibodies in the diagnosis and therapy of cancer.
Vaickus L, Foon KA. Vaickus L, et al. Cancer Invest. 1991;9(2):195-209. doi: 10.3109/07357909109044230. Cancer Invest. 1991. PMID: 1863875 Review.
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA. Meropol NJ, et al. Among authors: vaickus l. Clin Cancer Res. 1996 Apr;2(4):669-77. Clin Cancer Res. 1996. PMID: 9816217
Carboplatin for small cell lung cancer: progress toward greater efficacy and reduced toxicity.
Raghavan D, Perez R, Creaven P, Takita H, Loewen G, Vaickus L. Raghavan D, et al. Among authors: vaickus l. Semin Oncol. 1994 Jun;21(3 Suppl 6):1-8. Semin Oncol. 1994. PMID: 8052868 Review.
Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC, Pancook J, Goldrosen M, Han T, Foon KA, Vaickus L. Biddle WC, et al. Among authors: vaickus l. Cancer Res. 1990 May 15;50(10):2991-6. Cancer Res. 1990. PMID: 2334902
Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgery.
Meropol NJ, Petrelli NJ, Lipman BJ, Rodriguez-Bigas M, Hicks W, Douglass HO Jr, Smith JL, Rasey M, Blumenson LE, Vaickus L, Hayes FA, Agosti JM. Meropol NJ, et al. Among authors: vaickus l. Am J Surg. 1996 Sep;172(3):299-302. doi: 10.1016/s0002-9610(96)00106-7. Am J Surg. 1996. PMID: 8862090 Clinical Trial.
Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.
Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, Pincus S, Köhler H, Seon BK, Tahaoglu E, et al. Foon KA, et al. Among authors: vaickus l. Clin Cancer Res. 1995 Nov;1(11):1285-94. Clin Cancer Res. 1995. PMID: 9815923
Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell D, et al. Foon KA, et al. Among authors: vaickus l. J Immunother (1991). 1992 Apr;11(3):184-90. doi: 10.1097/00002371-199204000-00005. J Immunother (1991). 1992. PMID: 1515423 Clinical Trial.
Unusual gastrointestinal complications of interleukin-2 therapy.
Rahman R, Bernstein Z, Vaickus L, Penetrante R, Arbuck S, Kopec I, Vesper D, Douglass HO Jr, Foon KA. Rahman R, et al. Among authors: vaickus l. J Immunother (1991). 1991 Jun;10(3):221-5. doi: 10.1097/00002371-199106000-00009. J Immunother (1991). 1991. PMID: 1868046
Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, Breitmeyer J, Alger ME, Borden EC. Byhardt RW, et al. Among authors: vaickus l. J Interferon Cytokine Res. 1996 Nov;16(11):891-902. doi: 10.1089/jir.1996.16.891. J Interferon Cytokine Res. 1996. PMID: 8938564 Clinical Trial.
56 results
Jump to page
Feedback